Specific antibody response of common variable immunodeficiency patients to BNT162b2 COVID-19 vaccination

On March 11, 2020, the World Health Organization declared that coronavirus disease 2019 (COVID-19) was a pandemic.1 Since then, the disease has reached a 1% to 3% estimated overall mortality rate.2 COVID-19 severity ranges from asymptomatic to acute respiratory distress syndrome and possible death due to multiorgan failure.2 Therefore, to ameliorate the resultant poor health and social and economic consequences, prophylactic vaccines were developed. On December 11, 2020, the U.S. Food and Drug Administration issued the first emergency use authorization of Pfizer-BioNTech mRNA vaccine (BNT162b2) for COVID-19 prevention.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Letters Source Type: research